Shares in AstraZeneca saw a welcome boost on Thursday, as investors responded to the latest signals from the White House suggesting UK pharmaceutical imports could be spared from newly announced US tariffs. The news comes amid broader concerns over trade barriers affecting major global industries.
A fact sheet released alongside President Trump’s tariff announcement suggests that pharmaceuticals, alongside semiconductors and certain raw materials, will not be subject to higher import taxes. The exemption, though not yet finalised, provided relief for the Cambridge based pharmaceutical giant, which had been struggling in recent weeks amid fears of trade restrictions.
While the initial market reaction was positive, analysts warn that uncertainty remains. Sean Conroy of Shore Capital highlighted that it is still unclear whether a baseline 10% tariff could eventually apply to some drug imports. Given the complexity of global pharmaceutical supply chains, any shift in trade policy could have ripple effects on pricing and production strategies.
UBS analysts echoed these concerns, pointing out that the exemption appears valid for now but could be revisited. They also noted President Trump’s ongoing focus on the pharmaceutical sector, hinting at potential future measures aimed at encouraging companies to increase domestic production.
Meanwhile, AstraZeneca has sought to reassure investors, stating that it is actively assessing the situation and believes essential medicines should remain exempt.
Despite Thursday’s market optimism, analysts predict some level of volatility in the coming months as the full impact of US trade policy unfolds. With questions around potential phased tariffs and long-term regulatory shifts, investors remain watchful.
While some US-based pharmaceutical companies, including AbbVie and Merck, are seen as major beneficiaries of the news, UK firms like AstraZeneca and GSK will continue to navigate a complex and evolving trade landscape.
For now, at least, the pharmaceutical industry appears to have dodged a bullet. But with an unpredictable policy environment, all eyes will remain on Washington for further developments.
